Haoxi Health Technology Announces $4M Registered Direct Offering

Key Facts

In a move aimed at strengthening its cash position, Haoxi Health Technology announced a definitive agreement with specific investors for a registered direct offering totaling $4 million. The agreement involves the sale of 10 million Class A ordinary shares, or pre-funded warrants in lieu thereof, at a fixed price of $0.40 per share. This financing step reflects the company's efforts to secure necessary capital for its operations through direct agreements with investment parties.

Small-cap health technology firms often utilize direct offerings as a faster alternative to public underwritings, despite the potential dilution of existing shareholder equity. Compared to sector peers that have recently announced capital raises, the $0.40 offering price represents a significant discount to previous trading levels, a common pattern in direct financing to attract institutional interest per market data.

Traders are currently monitoring HAO stock, which stood at $1.07 at the close of July 9, 2026, as the gap between the market price and the offering price suggests potential short-term downward pressure. With no major upcoming catalysts in the economic calendar specifically for the health-tech sector, investors will focus on how the company deploys this new capital to scale operations and improve profit margins.